Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older.
• People who have been diagnosed with extensive-stage small cell lung cancer (ES-SCLC), confirmed by a laboratory test on a tissue or cell sample, before starting the combination treatment of atezolizumab, carboplatin, and etoposide.
• People whose cancer responded to treatment (completely, partially, or remained stable) after receiving at least three but no more than four cycles of atezolizumab, carboplatin, and etoposide.
• People with a good general health and activity level, rated 0 or 1 on a standard medical scale used in cancer trials (confirm with trial site).
• People who have had major surgery (such as chest, abdominal, or joint surgery) at least 28 days before joining, with no signs of wound complications or infection.
• People with brain metastases that are not causing symptoms, provided all of the following apply: no seizures in the past six months; any treatment for the brain metastases was completed at least 21 days before joining; no steroid use related to brain metastases for at least 7 days; and if the brain was previously treated with radiation, follow-up scans must show the metastases are stable or have shrunk.
• People with blood test results within the past 28 days showing healthy enough levels of white blood cells and platelets.
• People with kidney function test results within the past 28 days showing the kidneys are working well enough (confirm with trial site for specific values).
• People with liver function test results within the past 28 days showing the liver is working well enough (confirm with trial site for specific values).
• People with a heart that is pumping well enough, confirmed by a heart scan within the past 28 days (confirm with trial site for specific values).
• Women who could become pregnant must have a negative pregnancy blood test within 7 days before the first dose.
• Women who could become pregnant, and men who are sexually active with women who could become pregnant, must agree to use two forms of contraception (one highly effective and one effective method) starting at least 2 weeks before joining and continuing for four months after the last dose.
• Men must agree not to donate sperm during the study and for four months after the last dose.
• People who have voluntarily signed a consent form agreeing to take part, in line with the institution's requirements.

Who may not be able to join:

• People who were unable to tolerate atezolizumab during their previous treatment, leading to early stopping or frequent dose changes, as assessed by the treating doctor.
• People who have previously received gene therapy.
• People who have received preventive brain radiation (prophylactic cranial irradiation) or consolidation radiation to the chest.
• People who currently have an active viral, bacterial, or fungal infection that requires treatment.
• People with serious other illnesses, or personal, family, social, or geographical circumstances that the treating doctor believes would prevent proper participation in the study.
• People with a history of an autoimmune disease that required immune-suppressing treatment.
• People who have had a heart attack or unstable chest pain within the past 6 months.
• People known to have HIV, or who have an active hepatitis infection.
• Women who are pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.